Τρίτη 20 Οκτωβρίου 2020

 


Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
CONCLUSION: High-cost ovarian cancer admissions were three times more expensive than low-cost admissions. Fewer open and extended procedures with subsequently shorter lengths of stay may have contributed to decreasing inpatient costs over the study period. In this cohort of patients largely covered by Medicare, clinical factors outweigh socioeconomic factors as cost drivers. Understanding the relationship of disease-specific and social factors to cost will be important in informing future value-based...
Gynecologic Oncology
1w
A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.
CONCLUSION: Improved screening coverage has the largest potential for reducing cervical cancer incidence, though there is also a role for improved recall procedures and screening sensitivity. PMID: 32977987 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
CONCLUSIONS: This finding, combined with previous epidemiological literature and tissue-based analytical studies, provides further evidence that the small, isodiametric particles that dominate TCBP can migrate from the perineum and become lodged in distal structures in the female reproductive tract, where they may lead to an increased risk of developing ovarian carcinoma. PMID: 32977988 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
CONCLUSIONS: Use of HIPEC for ovarian cancer increased in the US after publication of a phase III clinical trial in a high-impact journal, though the absolute number of cases remains modest. Incorporation of HIPEC was associated with increased cost, hospital length of stay, ICU admission, and hospital-acquired complication rates. Further studies are needed in order to evaluate long-term outcomes, including morbidity and survival. PMID: 32977989 [PubMed - as supplied by publisher] (Source: Gynecologic...
Gynecologic Oncology
1w
The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes.
Authors: Chino J, Annunziata CM, Beriwal S, Bradfield L, Erickson BA, Fields EC, Fitch J, Harkenrider MM, Holschneider CH, Kamrava M, Leung E, Lin LL, Mayadev JS, Morcos M, Nwachukwu C, Petereit D, Viswanathan AN PMID: 32972783 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
CONCLUSIONS: Our findings will aid interpretation of EORTC QLQ-C30 scores in ovarian cancer and inform sample size calculations in future ovarian cancer trials with endpoints that are based on EORTC QLQ-C30 scales. PMID: 32972782 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
Authors: Eakin CM, Norton TJ, Monk BJ, Chase DM Abstract Poly(ADP-ribose) polymerase (PARP) inhibitors have rapidly emerged as a new class of daily oral chemotherapeutic agents that have the potential to dramatically alter the way in which primary peritoneal, fallopian tube and ovarian cancers are treated. However, the management of nausea and vomiting, the most common toxicities incurred by these agents, remains poorly understood. The purpose of this review is to provide an overview of...
Gynecologic Oncology
1w
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
CONCLUSIONS: Stratification of VSCC by p16- and p53-IHC has potential to be used routinely in diagnostic pathology. It results in the identification of three clinically distinct subtypes and may be used to guide treatment and follow-up, and in stratifying patients in future clinical trials. PMID: 32972785 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Management and outcomes of primary vaginal Cancer.
CONCLUSION: Surgery or radiation is effective treatment for vaginal cancer stage I and II. The addition of brachytherapy to external pelvic radiation increases survival in stages III-IV. PMID: 32972784 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Homologous recombination deficiency real-time clinical assays, ready or not?
Authors: Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A Abstract Cancers with deficiencies in homologous recombination-mediated DNA repair (HRR) demonstrate improved clinical outcomes and increased survival. Approximately 50% of high-grade serous ovarian cancers (HGSOC) exhibit homologous recombination deficiency (HRD). HRD can be caused by germline or somatic mutations of genes involved in the HR pathway. Given platinum-based...
Gynecologic Oncology
1w
A nurse- and peer-led psycho-educational intervention to support women with gynaecological cancers receiving curative radiotherapy: The PeNTAGOn randomised controlled trial - ANZGOG 1102.
CONCLUSIONS: There was no evidence that a nurse- and peer-led intervention had a beneficial effect on psychological distress compared to usual care. However, improved treatment readiness and lower health system and sexuality needs indicate the intervention may have addressed outcomes known to be important to this population. PMID: 32962898 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
CONCLUSION: Given its high specificity in targeting CDK4 and excellent anti-tumor efficacy with low toxicity, CDDD2-94 has potential to be developed as a standalone agent or in combination with targeted therapeutics for the treatment of ovarian cancer. PMID: 32958271 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
CONCLUSIONS: These results highlight the importance of spheroid size and shape on anti-cancer drug resistance and migration profiles. The results of this study can, therefore, help to elucidate general rules for ovarian cancer studies based on 3D samples. PMID: 32958270 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Water only fasting and its effect on chemotherapy administration in gynecologic malignancies.
CONCLUSION: A 48-h fast is well tolerated without increasing weight loss, hospital admissions, or chemotherapy dose reduction/delays. Fasting resulted in fewer treatment modifications and improved quality of life scores over the course of treatment. PMID: 32958269 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
CONCLUSIONS: The decision to use NACT should not be predicated on obesity alone, as the reduction in post-operative complications in obese patients is similar to non-obese patients. PMID: 32951891 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
CONCLUSIONS: Compared to surveillance, olaparib increases both the LYs and QALYs of women with newly diagnosed advanced ovarian cancer and with a germline or somatic BRCA mutation. Olaparib offers a cost-effective maintenance option for these women from a US third-party payer perspective. PMID: 32951894 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.
CONCLUSIONS: Somatic deficiencies in ERCC1, TUBB3, and KRAS are common in LGSOC in a population of minority patients. HRAS demonstrates decreased expression in tumors from older patients and recurrent tumors. PMID: 32951896 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
CONCLUSIONS: FGFR mutations are associated with worse PFS in UCC patients treated with definitive radiotherapy. These results warrant further validation in prospective studies. PMID: 32951893 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
A clinical classification system for grading platinum hypersensitivity reactions.
CONCLUSIONS: This classification system offers an objective means of grading pHSR severity and correlates with currently-used grading systems. PMID: 32951892 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm.
CONCLUSIONS: A restrictive prescribing practice allows for a significantly lower number of opioids to be prescribed to postoperative patients while maintaining patient satisfaction. There was no increase in opioid refill requests using a ROPA in patients undergoing surgery. PMID: 32951895 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
CONCLUSION(S): In this retrospective cohort study of women with advanced EOC undergoing PC, ABX treatment was associated with decreased PFS and OS. Mechanistic studies are needed to investigate the negative impact of ABX upon PC response in EOC. PMID: 32950250 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
CONCLUSION: Centralization of primary treatment of advanced ovarian cancer was associated with significantly increased complete cytoreduction, 5-year RS and DFS, and was found to be a significant independent factor for both RS and DFS. PMID: 32943206 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
1w
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer
Conclusions: TMT with CF and CP produced comparable outcomes. However, for dCRT, CF may be a superior regimen.Oncology (Source: Oncology)
Oncology
5d
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study
Conclusions: Despite the fact that second-line irinotecan plus gemcitabine combination therapy did not produce marked tumor shrinkage, it achieved a relatively high disease control rate of #x3e;65% with an acceptable toxicity profile. Hence, the combination of irinotecan plus gemcitabine may be considered for MPM treatment, with consideration of combination with immune checkpoint inhibitors as a potential next step.Oncology (Source: Oncology)
Oncology
5d
Sequencing PEComas: Viewing Unicorns through the Molecular Looking Glass
Oncology (Source: Oncology)
Oncology
1w
Endometrial Cancer: When Upfront Surgery Is Not an Option
Background and Summary: The management of endometrial cancer, in an ever-older population with considerable comorbidity, remains a challenge for gynecological and radiation oncologists.Key Message: The present paper reviews literature data on treatment options for endometrial cancer patients unfit for surgery.Oncology (Source: Oncology)
Oncology
1w
Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas
Conclusion: It becomes clear that lenvatinib treatment brings about tumor-related hemorrhages despite rapid suppression of tumor blood flow. We speculate that lenvatinib quickly blocks the feeding circulation, resulting in tumor hemorrhage by necrosis. Clinicians should pay careful attention to the development of life-threatening hemorrhages when treating large HCCs with lenvatinib.Oncology (Source: Oncology)
Oncology
1w
Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.
CONCLUSION: It becomes clear that lenvatinib treatment brings about tumor-related hemorrhages despite rapid suppression of tumor blood flow. We speculate that lenvatinib quickly blocks the feeding circulation, resulting in tumor hemorrhage by necrosis. Clinicians should pay careful attention to the development of life-threatening hemorrhages when treating large HCCs with lenvatinib. PMID: 33032274 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
1w
Endometrial Cancer: When Upfront Surgery Is Not an Option.
Authors: Barcellini A, Roccio M, Laliscia C, Zanellini F, Pettinato D, Valvo F, Mirandola A, Orlandi E, Gadducci A Abstract Background and Summary: The management of endometrial cancer, in an ever-older population with considerable comorbidity, remains a challenge for gynecological and radiation oncologists. Key Message: The present paper reviews literature data on treatment options for endometrial cancer patients unfit for surgery. PMID: 33032278 [PubMed - as supplied by publisher]...
Oncology
1w
High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases
Conclusion: Low preoperative MPO in serum might identify patients at high risk of recurrence and death after resection of colorectal liver metastases. Elevated preoperative MPO and high expression of MMP-9 in colorectal tumor tissue indicate an improved prognosis. The use of these biomarkers should be adjusted according to clinical characteristics.Oncology (Source: Oncology)
Oncology
1w
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients
Conclusions: After independent validation, the MELD-IGF-1 could be used to risk-stratify patients in clinical trials and for priority assignment for patients on liver transplantation waiting list.Oncology (Source: Oncology)
Oncology
1w
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.
CONCLUSIONS: After independent validation, the MELD-IGF-1 could be used to risk-stratify patients in clinical trials and for priority assignment for patients on liver transplantation waiting list. PMID: 33027788 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
1w
High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases.
CONCLUSION: Low preoperative MPO in serum might identify patients at high risk of recurrence and death after resection of colorectal liver metastases. Elevated preoperative MPO and high expression of MMP-9 in colorectal tumor tissue indicate an improved prognosis. The use of these biomarkers should be adjusted according to clinical characteristics. PMID: 33027796 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
1w
Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification
Conclusions: Our data suggest that patients with Her2 positivity or negativity when tumors have lower Her2 protein expression (2 + by IHC) have similar clinical outcomes. Further research is warranted in this cohort.Oncology (Source: Oncology)
Oncology
1w
TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
Conclusions: Our results highlight the superiority of TERT C228T in serum cfDNA compared with AFP and PIVKAII in the early diagnosis of primary HCC in NAFLD patients.Oncology (Source: Oncology)
Oncology
1w
TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
CONCLUSIONS: Our results highlight the superiority of TERT C228T in serum cfDNA compared with AFP and PIVKAII in the early diagnosis of primary HCC in NAFLD patients. PMID: 32998139 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
1w
Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification.
CONCLUSIONS: Our data suggest that patients with Her2 positivity or negativity when tumors have lower Her2 protein expression (2 + by IHC) have similar clinical outcomes. Further research is warranted in this cohort. PMID: 32998149 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
1w
Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters
Conclusions: Although larger studies are needed to confirm these results, our data open up new ways of investigation into the effects of AIs on QoL in HR+ BC patients.Oncology (Source: Oncology)
Oncology
1w
Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters.
CONCLUSIONS: Although larger studies are needed to confirm these results, our data open up new ways of investigation into the effects of AIs on QoL in HR+ BC patients. PMID: 32992318 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
1w
Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer
Conclusion: The current meta-analysis showed a moderate sensitivity and specificity of18F FDG PET or PET/CT for the prediction of OLNM in NSCLC patients. The DOR was low and the likelihood ratio scatter-gram indicated that18F FDG PET or PET/CT might not be useful for the prediction of OLNM in NSCLC patients and not for its exclusion.Oncology (Source: Oncology)
Oncology
1w
Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer.
CONCLUSION: The current meta-analysis showed a moderate sensitivity and specificity of 18F FDG PET or PET/CT for the prediction of OLNM in NSCLC patients. The DOR was low and the likelihood ratio scatter-gram indicated that 18F FDG PET or PET/CT might not be useful for the prediction of OLNM in NSCLC patients and not for its exclusion. PMID: 32980838 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
1w
Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study
Conclusions: Our results suggest that high-dose CDDP and comorbidities of cardiac disease and hypertension are independent risk factors for CDDP nephrotoxicity. Therefore, close monitoring of serum creatinine values during CDDP treatment is recommended for patients with these risk factors. In addition, Mg supplementation and administration of diuretics might be effective for prevention of CDDP nephrotoxicity.Oncology (Source: Oncology)
Oncology
1w
Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA
Conclusions: We describe for the first time mPEComa cases withFLCN mutations under LOH, further characterizing dysregulation of the mTOR pathway as a unifying theme in mPEC ­oma. Cumulatively, we demonstrate the feasibility and potential utility of segregating mPEComa byTSC,TFE3, andFLCN status via CGP in clinical care.Oncology (Source: Oncology)
Oncology
1w
Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
CONCLUSIONS: Our results suggest that high-dose CDDP and comorbidities of cardiac disease and hypertension are independent risk factors for CDDP nephrotoxicity. Therefore, close monitoring of serum creatinine values during CDDP treatment is recommended for patients with these risk factors. In addition, Mg supplementation and administration of diuretics might be effective for prevention of CDDP nephrotoxicity. PMID: 32966986 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
1w
Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA.
CONCLUSIONS: We describe for the first time mPEComa cases with FLCN mutations under LOH, further characterizing dysregulation of the mTOR pathway as a unifying theme in mPEC-oma. Cumulatively, we demonstrate the feasibility and potential utility of segregating mPEComa by TSC, TFE3, and FLCN status via CGP in clinical care. PMID: 32966992 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
1w
Circular RNA hsa_circ_0003204 promotes cervical cancer cell proliferation, migration, and invasion by regulating MAPK pathway.
Authors: Huang XB, Song KJ, Chen GB, Liu R, Jiang ZF, He YL Abstract Cervical cancer (CC) is the second most common malignancy in women worldwide. The mechanism underlying CC development remains unclear. Recently, Circular RNAs (circRNAs)have attracted attention because of its role in tumorigenesis. To investigate circRNAsin CC, RNA sequencing was employed to characterize circRNA expression profile between CC tissues and matched adjacent normal tissues. The expression of hsa_circ_0003204...
Cancer Biology and Therapy
5d
Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer.
Authors: Perez RE, Calhoun S, Shim D, Levenson VV, Duan L, Maki CG Abstract Prolyl endopeptidase (PREP), also known as prolyl oligopeptidase (POP), is an enzyme that cleaves short peptides (<30 amino acids in length) on the C-terminal side of proline. PREP is highly expressed in multiple carcinomas and is a potential target for cancer therapy. A potent inhibitor of PREP, Y-29794, causes long-lasting inhibition of PREP in mouse tissues. However, there are no reports on Y-29794 effects...
Cancer Biology and Therapy
5d
Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.
This study aimed to examine the expression of STAT1, PD-1, and PD-L1 and the correlation between selected markers in human epithelial ovarian cancer (EOC). The results showed that malignant tumors contained more STAT1, PD-1, and PD-L1 positive cells. The expression of STAT1 and PD-L1 was associated with age, whereas PD-1 and PD-L1 associated with histopathological type, in patients with ovarian tumors. Moreover, the expression of STAT1 was found to be associated with disease stages and the grade...
Cancer Biology and Therapy
5d
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
CONCLUSIONS: These results may support targeting treatment to small patient subgroups based on the presence of emerging EGFR mutations and provide a molecular rationale for rechallenging with a different anti-EGFR agent in patients who develop resistance. Prospective studies are needed to evaluate the efficacy of panitumumab in the EGFR p.S492R mutant population. PMID: 33026965 [PubMed - as supplied by publisher] (Source: Cancer Biology and Therapy)
Cancer Biology and Therapy
1w
miR-221-3p promotes hepatocellular carcinogenesis by downregulating O6-methylguanine-DNA methyltransferase.
This study aimed to investigate the influence of miR-221-3p and O6-methylguanine-DNA methyltransferase (MGMT) interaction in human hepatocellular carcinoma (HCC), thereby revealing a novel molecular mechanism of hepatic carcinogenesis involving miR-221-3p and MGMT. Fluorescence qPCR and immunoblot assays were performed to determine the expression of RNA and protein in HCC tissues and cell lines. We also employed the firefly and Renilla luciferase assay to verify the target relationship between...
Cancer Biology and Therapy
1w
Successful gene therapy requires targeting the vast majority of cancer cells.
Authors: Sagara T, Debeljak M, Wright CM, Anders NM, Liang H, Rudek MA, Ostermeier M, Eshleman JR, Matsushita Y Abstract Suicide gene therapy using gene-directed enzyme prodrug therapy (GDEPT) is based on delivering a gene-encoded enzyme to cells that converts a nontoxic prodrug into its toxic metabolite. The bystander effect is thought to compensate for inefficiencies in delivery and expression because the produced toxic metabolite can spread to adjacent non-expressing cells. The...
Cancer Biology and Therapy
1w
Long non-coding RNA ARAP1-AS1 promotes the proliferation and migration in cervical cancer through epigenetic regulation of DUSP5.
Authors: Min H, He W Abstract Emerging reports have indicated that long non-coding RNAs (lncRNAs) play pivotal roles in multiple cancers, containing cervical cancer. LncRNA ARAP1 antisense RNA 1 (ARAP1-AS1) was previously identified as a tumor-promoter in bladder cancer. However, the expression profile and possible modulation mechanism of ARAP1-AS1 in cervical cancer need to be further studied. In the current research, ARAP1-AS1 was discovered to exhibit a high level in cervical cancer...
Cancer Biology and Therapy
1w
LncRNA WWOX-AS1 sponges miR-20b-5p in hepatocellular carcinoma and represses its progression by upregulating WWOX.
This study was conducted to investigate the role of lncRNA WWOX antisense RNA 1 (WWOX-AS1) in HCC progression. Our present study illustrated that WWOX-AS1 was lowly expressed in HCC tissues and cell lines. High WWOX-AS1 expression was further confirmed to predict a favorable prognosis in HCC patients. Through functional assays, we observed that upregulated WWOX-AS1 was correlated with decreased cell proliferation, migration, epithelial to mesenchymal transition (EMT) process and increased cell apoptosis,...
Cancer Biology and Therapy
1w
[CD34+ cell selection methods, quality controls and expected results: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Authors: Calmels B, Gautier É, Magnani A, Magrin É, Mamez AC, Vaissié A, Yakoub-Agha I, Baudoux É Abstract CD34+ immunomagnetic positive selection allows for CD34+ hematopoietic progenitors separation from CD3+ lymphocytes subsets, usually from an apheresis product collected from a previously mobilized donor. This T-cell depleted stem cell graft is primarily intended for rare cases (around 2% of allotransplanted patients in France) of severe, persistent, symptomatic bi- or tri-cytopenia...
Bulletin du Cancer
5d
[Complementary and alternative medicine in cancer patients and randomized controlled trials].
Authors: Murat-Ringot A, Preau M, Piriou V Abstract More and more cancer patients around the world are using complementary and alternative medicine. They are mostly used as a complement to conventional care in decreasing the side effects of treatment and improving their quality of life. However, patients often use them without reporting it to their oncologists; the main reasons being the short duration of consultation and the fact that their oncologists do not support them due to a lack...
Bulletin du Cancer
5d
[Fundamental aspects of oncogenesis].
Authors: Lemaire J, Larrue R, Perrais M, Cauffiez C, Pottier N Abstract Tumorigenesis has traditionally been considered as a multi-step process involving the activation of oncogenes as well as the inactivation of tumor suppressor genes. However, the mechanisms driving cancer initiation and progression are not restricted to molecular alterations and instead should be viewed as a complex process that interfaces with the entire organism. This didactic review provides an integrated and global...
Bulletin du Cancer
5d
[Non endometroid endometrial cancer guidelines evaluation: A multicentric retrospective study].
DISCUSSION: Non endometrioid endometrial cancer guidelines applicability is difficult. This explicated by high age and comorbidity when surgical lymph node stadification is necessary. Using new staging technic will allow target management and better select lymph node staging indication. PMID: 33036741 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
5d
[Let us also take into account the TRALI-associated cell transplant risks].
Authors: Lafarge X PMID: 33036743 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
5d
[Musculoskeletal tumour surgery for adolescent and young-adult population: Collaboration between adult and pediatric surgeons is necessary].
Authors: Gouin F, Laurence V, Hamel A, Mascard E Abstract Orthopaedic surgery I has a key role on the medical pathway of adolescent and young-adult (AYA) patients with musculo-skeletal tumor from diagnosis, tumor resection, musculo-skeletal immediate or delayed reconstruction, to dealing with late complications and sequelae following reconstruction during childhood. Administrative authorizations, organization by health authorities as well as training courses are quite different for adult...
Bulletin du Cancer
5d
[Nomadism of patients treated by radiotherapy in Île-de-France: Does our health system have as much money to waste?]
CONCLUSION: Our results are similar to a report from the General Inspectorate of Social Affairs published in July 2011, which then pointed to an additional cost of between 4 and 6 million euros annually. The long-term care of cancer patients from their homes contributes to a deterioration in the quality of life linked to travel times, a delay in the care of potential treatment complications, and the spread of infectious diseases, such as COVID-19, and bacteria resistant to antibiotics. PMID:...
Bulletin du Cancer
5d
[Attachment and caregivers' life course facing cancer].
DISCUSSION: Detached-type insecure caregiver tend to minimize their signs of distress in the first time of disease. By contrast, preoccupied-type insecure adults tend to maximize distress signals. It's important to consider the specificity of each step of the process to better support caregivers. PMID: 33036740 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
5d
Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients.
DISCUSSION: Anti-PD-1/anti-PD-L1 re-challenge showed interesting clinical activity in selected patients, mainly in those achieving a long-term response upon the first ICPi course, that do not discontinue therapy because of disease progression, or that are able to keep a treatment-free period. PMID: 33032816 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[Evaluation of drug interactions in patients treated for a lung or digestive cancer].
CONCLUSION: Drug interactions remain a major concern in cancer hospitalized patients. It is important to continue and strengthen the collaboration between physicians and pharmacists in order to better prevent their occurrence. PMID: 33012503 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[The cost of the therapeutic education program "Eat better, move more through nutrition education" in patients with breast cancer].
CONCLUSION: This cost study, an accurate estimate of the production costs, allows to inform the decision-maker in term of pricing of such a program and to make the necessary adjustments in order to optimize the organization of this activity. PMID: 33012504 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[PARP inhibitors in breast cancer: Current clinical development and perspectives].
Authors: Robbe J, Moretta J, Vicier C, Sabatier R, Noguès C, Gonçalves A Abstract The association of a germline mutation in the BRCA1/2 genes in breast cancer leads to a higher genomic instability and, thus, a potential higher sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. In this review, we will summarize the different DNA-repair pathways including PARP-dependent mechanisms that support the use of PARP inhibitors. We will present clinical trials evaluating PARP inhibitors...
Bulletin du Cancer
1w
[Hot flushes and breast cancer with positive hormone receptors: Mechanisms and management].
Authors: Cavadias I, Rouzier R, Lerebours F, Héquet D Abstract Breast cancer is the most frequently diagnosed cancer in women and the first cause of cancer death in France. Among the different subtypes of breast cancer, the predominant form is characterized by positive hormone receptors (more than 70% of breast cancers). Hormone therapy thus plays a key role in the strategy of management of these cancers both in adjuvant and metastatic situations. The two types of adjuvant hormone therapy...
Bulletin du Cancer
1w
[ALL in adult patients: Contribution and limits of pediatric management].
The objective of this review is to discuss the benefit and the limits of pediatric therapeutic strategies in adults and the perspectives offered by new approaches including immunotherapies. PMID: 32981690 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
Sensitivity and polymorphism of Bethesda panel markers in Chinese population.
CONCLUSION: MSI-H cases showed earlier onset and higher proportion of mucinous carcinomas. Mononucleotide BAT26 and BAT25 exhibited higher sensitivity than dinucleotides D2S123, D17S250 and D5S346 in the Chinese population. The dinucleotide markers were highly polymorphic with high percent of heterozygosity, great variation in repeat length and non-normal distribution in Chinese population from Jiangsu Province. PMID: 32980144 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
Authors: Corbaux P, Sabatier R PMID: 32977934 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[Dosimetric factors related to postoperative pulmonary complications in locally advanced esophageal cancers treated with preoperative chemoradiotherapy: Literature review].
DISCUSSION: The most frequently identified dosimetric predictors for postoperative pulmonary complications are the V20 and the mean lung dose. Results of prospective studies would lead us to specify which of these parameters is most relevant for predicting the risk of postoperative pulmonary complications. PMID: 32977935 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[Lebanese physicians' attitude towards prostate cancer screening].
Authors: Ghayad T, Mekhael M, Gebara N, Eid R, Kourié HR, Haddad F, Nemr E PMID: 32977939 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[First results of a breast cancer risk assessment and management consultation].
CONCLUSION: This RBC evaluation consultation satisfies women and for a majority of them, modifies their methods of breast cancer screening. PMID: 32977936 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[Predictable toxicities with futures immunotherapies or combinations].
Authors: Mogenet A, Tomasini P, Greillier L, Barlesi F Abstract Immunotherapy by immune check-points inhibitors (ICIs) recently improved many solid tumors survival data. ICIs target and inhibit down-regulation signals between T cells and tumor cells involved in carcinogenesis, in order to enhance anti-tumor immunity. With few years' hindsight of ICIs utilization in daily practice, we learned about their safety profile. By releasing the brakes of the host immune-system, ICIs exposure leads...
Bulletin du Cancer
1w
[Physical activity after breast cancer diagnosis and survival: A systematic review].
CONCLUSION: Post-diagnosis PA reduces overall mortality and appears to impact specific breast cancer mortality and risk of recurrence. However, these results need to be confirmed by larger randomized trials. PMID: 32977937 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[Multidisciplinary team meeting in supportive care: 12  years of experience in a French comprehensive cancer center].
[Multidisciplinary team meeting in supportive care: 12 years of experience in a French comprehensive cancer center]. Bull Cancer. 2020 Sep 21;: Authors: Favier L, Bremaud N, Tharin Z, Blanc J, Bertaut A, Alavoine V, Dubief A, Truc G, Dorlean C, Coudert B Abstract In 2006, in response to DHOS Circular 2005/101, we have created a multidisciplinary supportive care meeting. As available literature covering this subject is rare, we report here our own experience. For this purpose,...
Bulletin du Cancer
1w
[Gastrointestinal symptoms revealing COVID-19  in Malian breast cancer patient undergoing chemotherapy].
[Gastrointestinal symptoms revealing COVID-19 in Malian breast cancer patient undergoing chemotherapy]. Bull Cancer. 2020 Sep 21;: Authors: Sidibe FM, Bathily M, Diarra B, Kone AS, Diabate K, Konate M, Cisse HL, Guindo I, Kone AA, Kone J, Berthe D, Ouattara BZ, Fofana Y, Sidibe A, Akpa AA, Dembele JP, Toure BA, Diakite A, Diarra IM, Kone AC, Soumare MD, Minta D, Dao S, Toloba Y, Diallo DA, Sidibe S Abstract In this review, we report a case of a bone's metastatic breast cancer...
Bulletin du Cancer
1w
[Nice-Saint-Paul de Vence 2020  recommendations for clinical practice: Management of metastatic and/or relapsing endometrial cancer].
[Nice-Saint-Paul de Vence 2020 recommendations for clinical practice: Management of metastatic and/or relapsing endometrial cancer]. Bull Cancer. 2020 Sep 18;: Authors: Alexandre J, Le Frere-Belda MA, Prulhiere K, Treilleux I, Leary A, Pomel C, Chargari C, Ducassou A, Joly F, groupe ARCAGY-GINECO Abstract Endometrial cancer is a common cancer in older women and is often associated with comorbidities. Management of metastatic disease and/or relapse requires a multidisciplinary...
Bulletin du Cancer
1w
[Management of immune checkpoint inhibitors-induced liver toxicity in cancer].
Authors: Lebossé F, Bancel B, Levrero M, Merle P Abstract Pharmacological immune checkpoint inhibitors (ICI) restore the anti-tumor properties of T-lymphocytes, but unfortunately can engender auto-immune-like disorders. Those, frequent and of variable severity, sometimes target the liver parenchyma. Liver toxicity of ICI firstly leads to alteration of liver function tests (ALFT) with a risk of clinical decompensation. The appearance of ALFT should lead the clinician to exclude a non-immunological...
Bulletin du Cancer
1w
How to improve clinical research in a department of radiation oncology.
This study overviewed the landscape of clinical research at our radiotherapy department. METHODS: We surveyed our institutional database of clinical trials to collect information for completed or ongoing radiation therapy clinical trials, from 2005 to December 2017 at the Lucien Neuwirth cancer institute. RESULTS: A total of 31 clinical trials were undertaken during the study period, of which 4 studies (12.9%) were industry-sponsored and 3 studies (9.7%) were launched by our radiotherapy...
Bulletin du Cancer
1w
[Leiomyosarcoma and angiomyomatous hamartoma: An hasardous association?]
Authors: Petitjean M, Kashi-Dakhil M, Hachemane S, Dakhil B, Zaimi R, Bagan P PMID: 32950243 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
1w
[Diagnostic strategy in pediatrics soft tissue sarcomas].
Authors: Collignon C, Brisse HJ, Lemelle L, Cardoen L, Gauthier A, Pierron G, Roussel A, Dumont B, Alimi A, Cordero C, Rouffiange L, Orbach D Abstract Soft tissue sarcomas in children are rare tumor, representing around 6 to 7% of children cancer. They spread mostly sporadically (90%) and therefore are rarely associated to an underlying constitutional genetic disease (10%). About half of those sarcomas are rhabdomyosarcomas and the others are a very heterogenous histologic group with various...
Bulletin du Cancer
1w
Editor's Note: Overexpression of Aurora-A Contributes to Malignant Development of Human Esophageal Squamous Cell Carcinoma
Clinical Cancer Research recent ...
5d
A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer
Purpose: Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinum and PARP inhibitors (PARPi). However, treatment stratification based on gBRCA mutational status alone is associated with heterogeneous responses. Experimental Design: We performed a seven-arm preclinical trial consisting of 471 mice, representing 12 unique PDAC patient-derived xenografts, of which nine were gBRCA mutated. From 179 patients whose...
Clinical Cancer Research recent ...
5d
Moving Beyond BRCA--Incorporating Molecular Assays into Ovarian Cancer Trials
PrOTYPE is a locked down assay validated to Institute of Medicine standards, using NanoString technology to classify high-grade serous ovarian cancer into four defined subgroups. Future directions will include prospective–retrospective analysis and prospective clinical validation to define the predictive role of this assay and its role in influencing treatment decisions. See related article by Talhouk et al., p. 5411
Clinical Cancer Research recent ...
5d
Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics
Purpose: Small-molecule inhibitors have had a major impact on cancer care. While treatments have demonstrated clinically promising results, they suffer from dose-limiting toxicities and the emergence of refractory disease. Considerable efforts made to address these issues have more recently focused on strategies implementing particle-based probes that improve drug delivery and accumulation at target sites, while reducing off-target effects. Experimental Design: Ultrasmall (<8 nm) core-shell...
Clinical Cancer Research recent ...
5d
TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better
IL15 and TIGIT blockade enhances the natural killer (NK) cell–mediated activity against MHC-I–deficient melanoma both in vitro and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT blockade, may represent a therapeutic approach for tumors, which lack HLA-I molecules thus escaping the CD8+ T cell–mediated control. See related article by Chauvin et al., p. 5520
Clinical Cancer Research recent ...
5d
Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a survival rate less than 5%. Multiple chemotherapeutic drugs have been tested to improve patient prognosis; however, the clinical efficacy of these treatments is low. One of the most controversial family of drugs are the proteasome inhibitors, which have displayed promising effects in preclinical studies, but low clinical performance. Here, we unravel a specific transcriptomic signature that discriminates a subgroup of patients...
Clinical Cancer Research recent ...
5d
Mouse Models of Oncoimmunology in Hepatocellular Carcinoma
Liver cancer is the fourth leading cause of cancer-related mortality worldwide and incidence is on the rise. Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with a complex etiology and limited treatment options. The standard-of-care treatment for patients with advanced HCC is sorafenib, a tyrosine kinase inhibitor that offers limited survival benefit. In the past years, therapeutic options for the treatment of advanced HCC have increased substantially, including additional...
Clinical Cancer Research recent ...
5d
Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma
Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared with other ovarian carcinomas. Nonetheless, current patient treatment continues to follow a "one-size-fits-all" approach. Even though tumor staging offers stratification, personalized treatments remain elusive. As ENOC shares many clinical and molecular features with its endometrial counterpart, we sought to investigate The Cancer Genome Atlas–inspired endometrial carcinoma (EC) molecular...
Clinical Cancer Research recent ...
5d
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Glioblastoma (WHO grade IV glioma) is the most common malignant primary brain tumor in adults. Survival has remained largely static for decades, despite significant efforts to develop new effective therapies. Immunotherapy and especially immune checkpoint inhibitors and programmed cell death (PD)-1/PD-L1 inhibitors have transformed the landscape of cancer treatment and improved patient survival in a number of different cancer types. With the exception of few select cases (e.g., patients with Lynch...
Clinical Cancer Research recent ...
5d
HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome
Purpose: To determine if a targeted exome panel utilizing matched normal DNA can accurately detect germline and somatic HLA genes in patients with synovial sarcoma (SS) and whether select HLA-A*02 genotypes are prognostic or predictive of outcome in metastatic SS. Experimental Design: Patients with metastatic SS consented to HLA typing by a Clinical Laboratory Improvement Amendments (CLIA)-certified test to determine eligibility for a clinical trial of NY-ESO-1–specific engineered T cells...
Clinical Cancer Research recent ...
5d
Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma
Despite standard of care for glioblastoma, including gross total resection, high-dose radiation, and dose-limited chemotherapy, this tumor remains one of the most aggressive and therapeutically challenging. The relatively small number of patients with this diagnosis compared with more common solid tumors in clinical trials commits new glioblastoma therapies to testing in small, underpowered, nonrandomized settings. Among approximately 200 registered glioblastoma trials identified between 2005 and...
Clinical Cancer Research recent ...
5d
Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Purpose: Emerging evidence indicates that gut microbiota dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). Proton pump inhibitors (PPI) are known to induce gut microbiota changes. However, little is known on the effects of PPIs on outcomes with ICI therapy, and it has not been explored in urothelial cancer treatment. Experimental Design: Individual–participant data from the advanced urothelial cancer trials, IMvigor210 (single-arm atezolizumab trial, n = 429) and...
Clinical Cancer Research recent ...
5d
Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations -- A Distinct Stem Cell Disorder
The tumor suppressor p53 exerts pivotal roles in hematopoietic stem cell (HSC) homeostasis. Mutations of the TP53 gene have recently been described in individuals with clonal hematopoiesis conferring substantial risk of developing blood cancers. In patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), TP53 aberrations—mutations, deletions, and a combination thereof—are encountered at a constant frequency of approximately 10%. These aberrations affect HSCs transforming them...
Clinical Cancer Research recent ...
5d
Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors
Purpose: Perivascular epithelioid cell tumors (PEComa) are rare mesenchymal neoplasms. mTOR inhibitors are the most active agents in PEComa and in patients progressing to mTOR inhibitors, other available therapies have limited benefit. Preclinical evidences showed a cross-talk between the mTOR pathway and estrogen receptor signaling. This provided a rationale for adding an antiestrogen treatment in female patients becoming resistant to mTOR inhibitors. Experimental Design: Since April 2018,...
Clinical Cancer Research recent ...
5d
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer
Purpose: The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor–positive (HR+) metastatic breast cancer (MBC). Secondary objectives evaluated extracranial response, abemaciclib pharmacokinetics, brain metastases tissue exposure, and safety. Patients and Methods: This nonrandomized, phase II study (NCT02308020) enrolled patients in tumor subtype–specific...
Clinical Cancer Research recent ...
5d
Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology
Purpose: Glioblastoma (GBM) is one of the deadliest cancers with no cure. While conventional MRI has been widely adopted to examine GBM clinically, accurate neuroimaging assessment of tumor histopathology for improved diagnosis, surgical planning, and treatment evaluation remains an unmet need in the clinical management of GBMs. Experimental Design: We employ a novel diffusion histology imaging (DHI) approach, combining diffusion basis spectrum imaging (DBSI) and machine learning, to detect,...
Clinical Cancer Research recent ...
5d
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma
Purpose: Induction cisplatin and gemcitabine chemotherapy is a standard treatment for locally advanced nasopharyngeal carcinoma (NPC). Inhibition of VEGF axis has been shown to promote maturation of microvasculature and improve perfusion. We conducted a four-arm study to assess the effect of two doses of either sunitinib or bevacizumab with chemotherapy in NPC. Patients and Methods: Patients with treatment-naïve locally advanced NPC were treated with three cycles of 3-weekly cisplatin and gemcitabine...
Clinical Cancer Research recent ...
5d
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Purpose: Gene expression–based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported...
Clinical Cancer Research recent ...
5d
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Purpose: Romidepsin dosing recommendations for patients with malignancy and varying degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell lymphoma. We conducted a multicenter phase I clinical trial (ETCTN-9008) via the NCI Organ Dysfunction Working Group to investigate safety, first cycle MTD, and pharmacokinetic profile of romidepsin in this setting. Patients and Methods: Patients with select advanced solid tumors or hematologic malignancies were stratified...
Clinical Cancer Research recent ...
5d
A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy
Purpose: Bevacizumab is considered a promising therapy for brain necrosis after radiotherapy, while some patients fail to derive benefit or even worsen. Hence, we developed and validated a radiomics model for predicting the response to bevacizumab in patients with brain necrosis after radiotherapy. Experimental Design: A total of 149 patients (with 194 brain lesions; 101, 51, and 42 in the training, internal, and external validation sets, respectively) receiving bevacizumab were enrolled. In...
Clinical Cancer Research recent ...
5d
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Purpose: ZEN-3694 is a bromodomain extraterminal inhibitor (BETi) with activity in androgen-signaling inhibitor (ASI)-resistant models. The safety and efficacy of ZEN-3694 plus enzalutamide was evaluated in a phase Ib/IIa study in metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods: Patients had progressive mCRPC with prior resistance to abiraterone and/or enzalutamide. 3+3 dose escalation was followed by dose expansion in parallel cohorts (ZEN-3694 at 48 and 96...
Clinical Cancer Research recent ...
5d
PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Purpose: In both the IMpassion 130 trial in the metastatic setting and in Keynote 522 in the neoadjuvant setting, patients with triple-negative breast cancer (TNBC) showed benefit from PD-1 axis immunotherapy. Here, we assess PD-L1 expression on both tumor and immune cells using quantitative immunofluorescence to assess association with benefit from neoadjuvant durvalumab concurrent with chemotherapy in TNBC. Experimental Design: Pretreatment core needle biopsies (n = 69) were obtained from...
Clinical Cancer Research recent ...
5d
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer
Purpose: The recombinant fusion protein ipafricept blocks Wnt signaling, and in combination with gemcitabine and nab-paclitaxel caused tumor regression in xenografts. This phase Ib study evaluated the combination of ipafricept with nab-paclitaxel + gemcitabine in patients with untreated metastatic pancreatic adenocarcinoma (mPDAC). Patients and Methods: Dose escalation started with standard dose nab-paclitaxel + gemcitabine and ipafricept (3.5 mg/kg days 1, 15). Because of fragility fractures...
Clinical Cancer Research recent ...
5d
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment
Purpose: Malignant pleural mesothelioma (MPM) is considered an orphan disease with few treatment options. Despite multimodality therapy, the majority of MPMs recur and eventually become refractory to any systemic treatment. One potential mechanism underlying therapeutic resistance may be intratumor heterogeneity (ITH), making MPM challenging to eradicate. However, the ITH architecture of MPM and its clinical impact have not been well studied. Experimental Design: We delineated the immunogenomic...
Clinical Cancer Research recent ...
5d
Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Purpose: Immune checkpoint blockade has demonstrated clinical benefits across multiple solid tumor types; however, resistance and relapse often occur. New immunomodulatory targets, which are highly expressed in activated immune cells, are needed. MEDI0562, an agonistic humanized mAb, specifically binds to the costimulatory molecule OX40. This first-in-human study evaluated MEDI0562 in adults with advanced solid tumors. Patients and Methods: In this phase I, multicenter, open-label, single-arm,...
Clinical Cancer Research recent ...
5d
Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion
Purpose: T-cell recruitment, survival, and proliferation are the important limitations to chimeric antigen receptor (CAR) T cells therapy in the treatment of solid tumors. In this study, we engineered CAR-T cells to coexpress cytokines IL7 and CCL21 (7 x 21 CAR-T), a cytokine combination in order to improve proliferation and chemotaxis of CAR-T cells. Experimental Design: CLDN18.2-specific second-generation CAR-T cells coexpressing cytokines were prepared using retroviral vector transduction....
Clinical Cancer Research recent ...
5d
Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial
Purpose: Non–small cell lung cancer (NSCLC) is a fatal disease with poor prognosis. A membrane-bound form of Hsp70 (mHsp70) which is selectively expressed on high-risk tumors serves as a target for mHsp70-targeting natural killer (NK) cells. Patients with advanced mHsp70-positive NSCLC may therefore benefit from a therapeutic intervention involving mHsp70-targeting NK cells. The randomized phase II clinical trial (EudraCT2008-002130-30) explores tolerability and efficacy of ex vivo–activated NK...
Clinical Cancer Research recent ...
5d
Selected Articles from This Issue
Clinical Cancer Research recent ...
5d
Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer
Purpose: (4S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) is a radiopharmaceutical for PET imaging of system xC– activity, which can be upregulated in prostate cancer. We present data on the first evaluation of patients with newly diagnosed or recurrent prostate cancer with this radiopharmaceutical. Experimental Design: Ten patients with primary and 10 patients with recurrent prostate cancer were enrolled in this prospective multicenter study. After injection of 300 MBq of 18F-FSPG,...
Clinical Cancer Research recent ...
5d
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer--Letter
Clinical Cancer Research recent ...
5d
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
Purpose: Natural killer (NK) cells play a critical role in tumor immunosurveillance. Multiple activating and inhibitory receptors (IR) regulate NK-cell–mediated tumor control. The IR T-cell immunoglobulin and ITIM domain (TIGIT) and its counter-receptor CD226 exert opposite effects on NK-cell–mediated tumor reactivity. Experimental Design: We evaluated the frequency, phenotype, and functions of NK cells freshly isolated from healthy donors and patients with melanoma with multiparameter flow...
Clinical Cancer Research recent ...
5d
iGLASS: imaging integration into the Glioma Longitudinal Analysis Consortium
GliomaglioblastomaimagingradiogenomicsGLASSiGLASS
Neuro-Oncology - current issue
6d
Highlights from the Literature
Neuro-Oncology - current issue
6d
Forthcoming Meetings
Edited by Jennie W. Taylor
Neuro-Oncology - current issue
6d
Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies
This study aims at examining the frequency, patterns and molecular etiologies of such inter-tumoral MMR discordances. We analyzed a cohort of 2159 colorectal cancer (CRC) patients collected over a 5-year period and found that 1.3% of the patients (27/2159) had  ≥ 2 primary CRCs, and 25.9% of the patients with ≥ 2 primary CRCs (7/27) exhibited inter-tumoral MMR discordance. We then combined the seven MMR-discordant CRC patients with three additional MMR-discordant GIT carcinoma patients and evaluated...
Familial Cancer
6d
FRAMe: Familial Risk Assessment of Melanoma —a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma
AbstractGermline mutations inCDKN2A greatly increase risk of developing cutaneous melanoma. We have constructed a risk prediction model, Familial Risk Assessment of Melanoma (FRAMe), for estimating the likelihood of carrying a heritableCDKN2A mutation among Australian families, where the prevalence of these mutations is low. Using logistic regression, we analysed characteristics of 299 Australian families recruited through the Sydney site of GenoMEL (international melanoma genetics consortium) with...
Familial Cancer
1w
New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer
(Source: Familial Cancer)
Familial Cancer
1w
Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital
The objective of this study was to examine whether women undergoing prophylactic laparoscopic BSO felt they were adequately informed about post-operative outcomes. A telephone interview was conducted among 46 women undergoing laparoscopic BSO to collect detailed information regarding surgical outcomes, complications, symptoms, and time to return to daily activities. The average age at surgery was 45.0  years (range 34–66) and 67% of women underwent BSO prior to age 50. The mean reported hospital...
Familial Cancer
1w
Quantitative evaluation of MSI testing using NGS detects the imperceptible microsatellite changed caused by MSH6 deficiency
AbstractMicrosatellite instability (MSI) is an effective biomarker for diagnosing Lynch syndrome (LS) and predicting the responsiveness of cancer therapy. MSI testing is conventionally performed by capillary electrophoresis, and MSI status is judged by visual assessment of allele size change. Here, we attempted to develop a quantitative evaluation model of MSI using next-generation sequencing (NGS). Microsatellite markers were analyzed in tumor and non-tumor tissues of colorectal cancer patients...
Familial Cancer
1w
Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy
Abstract Renal cell carcinoma (RCC) is the most common malignant kidney tumor and has a high incidence rate. Circular RNAs (circRNAs) are noncoding RNAs with widespread distribution and diverse cellular functions. They are highly stable and have organ- and tissue-specific expression patterns. CircRNAs have essential functions as microRNA sponges, RNA-binding protein- and transcriptional regulators, and protein translation templates. Recent reports have shown that circRNAs are...
Latest Results for Molecular Cancer
6d
Smoking Cessation for Cancer Patients, Lumbar Puncture and Spinal Hematoma, and more
Editor's Summary by Mary McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the October 13, 2020 issue (Source: JAMA: This Week's Audio Commentary)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
MedWorm Cancer & Oncology Podcasts
6d
Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
CONCLUSIONS: The survival for patients with MBC in New Zealand is very similar to other developed countries. Patients with dnMBC had a much better prognosis than those with recurrent disease. Patients with triple negative disease or non-luminal HER2 positive disease had the worst prognosis. The prognosis for patient with rMBC improved the longer the time from diagnosis to the development of metastases. PMID: 33044617 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Breast Cancer
6d
Subjective and objective cognitive functioning among patients with breast cancer: effects of chemotherapy and mood symptoms.
CONCLUSION: Our findings suggest cognitive impairments in the domain of executive functioning among patients with BC who received chemotherapy. Providing relevant suggestions or strategies of managements for these negative consequences may help increase the long-term quality of life of patients with BC. PMID: 33030667 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Breast Cancer
6d
An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer.
Authors: Heervä E, Väliaho V, Salminen T, Nieminen L, Carpelan A, Kurki S, Sundström J, Huhtinen H, Rantala A, Carpén O, Minn H, Österlund P, Ålgars A, Ristamäki R PMID: 33044880 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
6d
Management of low-grade cervical cytology in young women. Cohort study from Denmark.
CONCLUSIONS: The choice of management strategy influences both the detection rate for severe lesions (CIN3+) and the proportion of women followed up for potentially insignificant findings. PMID: 33030976 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
6d
Oncological therapy to Swedish men with metastatic penile cancer 2000-2015.
CONCLUSION: The use of oncological treatment was below recommendations in guidelines but increased during the study period. Treatment was given predominantly to men with c/pN2-3 and M1-disease. Survival was higher among men treated with curative intent; this could be due to patient selection bias. PMID: 33030399 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
6d
HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma.
CONCLUSION: HE4 is a feasible biomarker in the treatment monitoring and prognostic stratification of patients with HGSC. Specifically, the serum level of HE4 at first relapse was associated with the survival of patients and it may be a useful complementary tool in the selection of second line treatments. This is to the best of our knowledge the first time this finding has been reported. PMID: 33030975 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
6d
Clinical iterative model development improves knowledge-based plan quality for high-risk prostate cancer with four integrated dose levels.
CONCLUSION: KBP improved plan quality and consistency among treatment plans for high-risk prostate cancer. Model tuning using KBP-based clinical plans further improved model outcome. PMID: 33030972 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
6d
Trends in pre-operative needle biopsy use in invasive breast cancer diagnosis: a Dutch nationwide population study.
CONCLUSION: Results suggest that nationwide, clinics prioritise reliability and availability of ER and HER2 status, replacing FNAC by CNB. However, for optimal treatment planning for all patients, availability of pre-operative receptor status warrants further improvement. PMID: 33030998 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
6d
Quality of life in patients with cancer during the COVID-19 pandemic - a Danish cross-sectional study (COPICADS).
CONCLUSION: Danish patients with cancer during the COVID-19 pandemic did not have lower scores of QoL and emotional functioning compared to the Danish 'Barometer Study'. However, the study suggests that concerns of contracting COVID-19 was correlated with lower scores of QoL. PMID: 33031010 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
6d
Rehabilitation and palliative care for socioeconomically disadvantaged patients with advanced cancer: a scoping review.
CONCLUSION: Existing research within this research field is sparse. Future research should focus more on how best to reach and support socioeconomically disadvantaged people with advanced cancer in community-based rehabilitation and palliative care. PMID: 33021852 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
RBE for proton radiation therapy - a Nordic view in the international perspective.
CONCLUSIONS: The need for collaboration between the clinical proton centres in establishing common platforms and perspectives for treatment planning evaluation and optimisation is highlighted as well as the need of close interaction with the research academic groups that could offer a complementary perspective and actively help developing methods and tools for clinical implementation of the more complex metrics for considering the variable effectiveness of the proton beams. PMID: 33000988 [PubMed...
Acta Oncologica
1w
Reduction of inter-observer contouring variability in daily clinical practice through a retrospective, evidence-based intervention.
CONCLUSION: We detected significant contouring IOV in routine practice using easily accessible retrospective data and successfully decreased IOV in our clinic through a reflective intervention. Continued application of this approach may aid improvements in practice standardization and enhance quality of care. PMID: 32988249 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?
CONCLUSION: This retrospective study, investigating postoperative RT in primary localized meningeal SFT patients, suggests that combining RT to surgery in the management of this patient population may reduce the risk for local failures. PMID: 32988268 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care.
CONCLUSIONS: The clinical registry framework provides an empirical basis for evidence-based development of high-quality and equitable cancer care. The registries can be used to follow implementation of new treatment principles and monitor patterns of care across geographical areas and patient groups. At the same time, the lessons learnt suggest that further developments and coordination are needed to utilize the full potential of the registry initiative in cancer care. PMID: 32981417 [PubMed...
Acta Oncologica
1w
A petition for all patients with hidradenitis suppurativa to receive the HPV vaccine.
Authors: Deutsch A, Cohen SR, Blasiak RC PMID: 32975480 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
Hypofractionated stereotactic photon radiotherapy of choroidal melanoma: 20-year experience.
CONCLUSION: Hypofractionated stereotactic photon radiotherapy showed a high rate of local tumor control for choroidal melanoma and an acceptable rate of radiogenic side effects. PMID: 32969745 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
Authors: Andersen MA, Valentin R, Dissing Sjö L, Borgwardt L, Schmiegelow K, Andersen MK, Marvig RL, Yde CW, Niemann CU PMID: 32970500 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
Metastatic uveal melanoma managed with best supportive care.
Authors: Rantala ES, Hernberg MM, Lundin M, Lundin J, Kivelä TT PMID: 32960119 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
Adherence to international recommendations in the governance and organisation of Nordic cervical cancer screening programmes.
CONCLUSIONS: The Nordic cervical cancer screening programmes have substantially decreased cancer burden despite not fully adhering to many of the recommendations. The presented gaps in adherence suggest that there is room for improvement in the screening programmes. Establishing clearer governance structures would still increase the ability to manage changes such as implementing HPV testing as the primary screening method or modifying the programme when HPV vaccinated cohorts of women enter the target...
Acta Oncologica
1w
Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy.
CONCLUSION: MR-guided daily-adaptive SBRT seems a feasible and accurate strategy for treating prostate cancer with ablative doses. IGRT with the use of fiducials provides a comparable level of accuracy and acceptable real-dose distribution over treatment fractions. Future study will provide additional data regarding the tolerability and the clinical outcome of this new technological approach. PMID: 32945701 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
Robust treatment planning of dose painting for prostate cancer based on ADC-to-Gleason score mappings - what is the potential to increase the tumor control probability?
CONCLUSIONS: TCP increases with DPBN plans optimized in a TPS were found more likely with a high precision mapping of image data into dose-responses and a high certainty of the tumor positioning. These findings motivate further development to ensure precise mappings of image data into dose-responses and to ensure a high spatial certainty of the tumor positioning when implementing DPBN clinically. PMID: 32941092 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
Voluntary wheel running can lead to modulation of immune checkpoint molecule expression.
CONCLUSION: B16 tumors displayed upregulated expression of immune regulatory molecules and decreased tumor growth in response to PA. However, combining PA with PD-1 or PD-L1 blockade did not lead to a further augmented inhibition of tumor growth. PMID: 32935602 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w
Cancer incidence in non-immigrants and immigrants in Norway.
CONCLUSION: National registries should continuously monitor and present cancer incidence stratified on important population subgroups such as country of birth. This can help assess population subgroup specific needs for cancer prevention and treatment, and could eventually help reduce the morbidity and mortality of cancer. PMID: 32930622 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
1w

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου